These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7485666)

  • 1. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program.
    Hagan H; Jarlais DC; Friedman SR; Purchase D; Alter MJ
    Am J Public Health; 1995 Nov; 85(11):1531-7. PubMed ID: 7485666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users.
    Bialek SR; Bower WA; Mottram K; Purchase D; Nakano T; Nainan O; Williams IT; Bell BP
    J Urban Health; 2005 Sep; 82(3):468-78. PubMed ID: 16049202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syringe exchange and risk of infection with hepatitis B and C viruses.
    Hagan H; McGough JP; Thiede H; Weiss NS; Hopkins S; Alexander ER
    Am J Epidemiol; 1999 Feb; 149(3):203-13. PubMed ID: 9927214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program.
    Hagan H; Thiede H
    J Urban Health; 2000 Sep; 77(3):369-82. PubMed ID: 10976611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004.
    Burt RD; Hagan H; Garfein RS; Sabin K; Weinbaum C; Thiede H
    J Urban Health; 2007 May; 84(3):436-54. PubMed ID: 17356901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users.
    Estrada AL
    Public Health Rep; 2002; 117 Suppl 1(Suppl 1):S126-34. PubMed ID: 12435836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program.
    Des Jarlais DC; Fisher DG; Newman JC; Trubatch BN; Yancovitz M; Paone D; Perlman D
    Am J Public Health; 2001 Nov; 91(11):1791-2. PubMed ID: 11684603
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV, hepatitis B and sexual practices in the street-recruited injecting drug users of Calcutta: risk perception versus observed risks.
    Panda S; Chatterjee A; Bhattacharjee S; Ray B; Saha MK; Bhattacharya SK
    Int J STD AIDS; 1998 Apr; 9(4):214-8. PubMed ID: 9598748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug injection rates and needle-exchange use in New York City, 1991-1996.
    Marmor M; Shore RE; Titus S; Chen X; Des Jarlais DC
    J Urban Health; 2000 Sep; 77(3):359-68. PubMed ID: 10976610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to hepatitis B virus vaccination at syringe exchange sites.
    Altice FL; Bruce RD; Walton MR; Buitrago MI
    J Urban Health; 2005 Mar; 82(1):151-61. PubMed ID: 15746385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin.
    Stark K; Bienzle U; Vonk R; Guggenmoos-Holzmann I
    Int J Epidemiol; 1997 Dec; 26(6):1359-66. PubMed ID: 9447418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high.
    Goldberg D; Cameron S; McMenamin J
    Commun Dis Public Health; 1998 Jun; 1(2):95-7. PubMed ID: 9644121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: "Syringe exchange and risk of infection with hepatitis B and C viruses".
    Voth EA
    Am J Epidemiol; 2000 Jan; 151(2):207-8. PubMed ID: 10645825
    [No Abstract]   [Full Text] [Related]  

  • 14. Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase.
    Copeman M
    Med J Aust; 2003 Jul; 179(2):119; author reply 119. PubMed ID: 12864712
    [No Abstract]   [Full Text] [Related]  

  • 15. Knowledge of hepatitis among active drug injectors at a syringe exchange program.
    Carey J; Perlman DC; Friedmann P; Kaplan WM; Nugent A; Deutscher M; Masson CL; Des Jarlais DC
    J Subst Abuse Treat; 2005 Jul; 29(1):47-53. PubMed ID: 15979531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy of needle exchange programs in the prevention of HIV and hepatitis infection among injecting drug users].
    Takács IG; Demetrovics Z
    Psychiatr Hung; 2009; 24(4):264-81. PubMed ID: 19949245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004.
    Falster K; Kaldor JM; Maher L;
    J Urban Health; 2009 Jan; 86(1):106-18. PubMed ID: 18979201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City.
    Pratt CC; Paone D; Carter RJ; Layton MC
    Am J Public Health; 2002 Aug; 92(8):1254-6. PubMed ID: 12144980
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
    Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
    Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of needle exchange programs in HIV prevention.
    Vlahov D; Junge B
    Public Health Rep; 1998 Jun; 113 Suppl 1(Suppl 1):75-80. PubMed ID: 9722812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.